By Benjamin Chiou
Date: Friday 12 Dec 2025
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
"The funding environment for biotech has been at a lull relative to the...
or login to read the full story
Email this article to a friend
or share it with one of these popular networks:
You are here: news